BioNTech gibt auf de
BioNTech gibt auf der 43. J.P. Morgan Healthcare-Konferenz Updates zur Geschäfts- und Pipeline-Entwicklung
January 14, 2025 06:45 ET | BioNTech SE
BioNTech fokussiert sich in der Umsetzung der Onkologie-Strategie auf tumorübergreifende (Pan-Tumor-) Therapieansätze basierend auf Kombinationen mit BNT327/PM8002 sowie den...
BioNTech Provides Bu
BioNTech Provides Business and Pipeline Updates at 43rd Annual J.P. Morgan Healthcare Conference
January 14, 2025 06:45 ET | BioNTech SE
Executing in oncology with investigational BNT327/PM8002 combinations and mRNA cancer immunotherapy candidates as pan-tumor treatment approaches BioNTech aims to develop BNT327/PM8002 as a...
Alkeus Pharma Logo 2024.png
Alkeus Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference
January 07, 2025 10:52 ET | Alkeus Pharmaceuticals
Alkeus Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference on January 14.
quantro_logo_for GNW.png
QUANTRO Therapeutics achieves breakthrough in transcriptomic drug discovery with first successful simultaneous 10-target multiplex-screening
January 07, 2025 08:30 ET | QUANTRO Therapeutics GmbH
QUANTRO’s proprietary time-resolved functional transcriptomic discovery platform accelerates target screening for complex indications in oncology and inflammationQUANTRO CEO Dr. Michael Bauer to...
kailera logo.png
Kailera Therapeutics to Present at 43rd Annual J.P. Morgan Healthcare Conference
January 06, 2025 08:15 ET | Kailera Therapeutics, Inc.
Ron Renaud, Kailera's President and Chief Executive Officer, will present at the 43rd Annual J.P. Morgan Healthcare Conference on January 14, 2025.
Artios Pharma to Present at the 43rd Annual J.P. Morgan Healthcare Conference
December 19, 2024 08:00 ET | Artios Pharma
CAMBRIDGE, United Kingdom and NEW YORK, December 19, 2024 – Artios Pharma Limited (“Artios”), a clinical-stage biotech company led by pioneers of DNA damage response (“DDR”) drug development, today...
invios-Logo-RGB-small.jpg
invIOs to present progress across oncology pipeline during JP Morgan Week 2025
December 16, 2024 09:00 ET | invIOs GmbH
VIENNA, Dec. 16, 2024 (GLOBE NEWSWIRE) -- invIOs GmbH (“invIOs”), a privately held biotechnology company developing novel therapies for cancer, will be participating in JP Morgan week activities in...
Logo 1200x628.jpg
CytoSorbents to Host Investor Meetings in San Francisco During J.P. Morgan Healthcare Conference Week
December 12, 2024 07:00 ET | CytoSorbents
CytoSorbents Is Scheduling In-Person Investor Meetings During the JP Morgan Healthcare Conference from Jan 13-15, 2025 in San Francisco.
wuFVh3u3_400x400.jpg
Inaugural Pre-JPM Partnering Week to Wrap Up 2024, Prepare for 2025
August 29, 2024 07:30 ET | Big4Bio
New life science partnering conference to debut that prepares and helps industry dealmakers and stakeholders for the JP Morgan Healthcare Conference week
BioNTech stellt stra
BioNTech stellt strategische Prioritäten für 2024 auf der 42. jährlichen J.P. Morgan Healthcare-Konferenz vor
January 09, 2024 06:45 ET | BioNTech SE
BioNTech rechnet mit zehn oder mehr laufenden potenziell zulassungsrelevanten Studien bis Ende 2024Der Aufbau kommerzieller Kapazitäten zur Vorbereitung auf Produkteinführungen soll Ende 2025...